What is the appropriate management for a woman with uterine fibroids, taking into account her symptoms, age, and desire for fertility?

Management of Uterine Fibroids

For symptomatic uterine fibroids, begin with medical therapy using a levonorgestrel-releasing IUD or combined oral contraceptives as first-line treatment, escalate to GnRH antagonists with add-back therapy if initial treatment fails, and reserve surgical intervention (myomectomy for fertility preservation or hysterectomy for definitive cure) for patients who do not respond to medical management or have severe bulk symptoms. 1, 2, 3

Asymptomatic Fibroids

• No intervention is required for asymptomatic fibroids regardless of size or location. 3
• Reassure patients that malignancy risk is negligible (leiomyosarcoma occurs in <1 in 1000 cases). 4
• Document fibroid characteristics (location, size, relationship to uterine cavity) at baseline for future reference. 2

Symptomatic Fibroids: Medical Management Algorithm

First-Line Medical Therapy

All symptomatic patients should trial medical therapy before considering invasive procedures, regardless of fertility goals. 3

For Heavy Menstrual Bleeding:

• Levonorgestrel-releasing IUD is the most effective hormonal option, reducing menstrual blood loss and providing long-term symptom control. 2, 3
• Tranexamic acid (1-1.5 g orally every 6-8 hours) is the best non-hormonal alternative, significantly reducing menstrual blood loss without affecting fertility. 2, 3
• Combined oral contraceptives effectively control bleeding in women not attempting conception. 2, 3
• NSAIDs reduce both bleeding volume and dysmenorrhea and may be combined with hormonal therapy. 1, 3

For Bulk Symptoms (Pelvic Pressure, Urinary Frequency):

• Medical therapy alone is unlikely to provide sufficient relief for large fibroids (>8-10 cm). 1
• Consider GnRH-based therapy or selective progesterone receptor modulators as a bridge to surgery or menopause. 1, 2

Second-Line Medical Therapy

When first-line options fail or for preoperative fibroid reduction:

• GnRH antagonists (elagolix, relugolix) with add-back estrogen-progestin therapy reduce fibroid volume by 18-30% and control bleeding symptoms. 2, 3
• GnRH agonists (leuprolide acetate) shrink fibroids and correct anemia but require add-back therapy when used >3-6 months to prevent bone density loss and hypoestrogenic symptoms (hot flashes, headaches). 1, 2
• Selective progesterone receptor modulators (ulipristal acetate) reduce fibroid volume by approximately 30% after one course and up to 70% after four courses, with Level I, A evidence for symptomatic relief. 1, 3

Preoperative Optimization

• Correct anemia before elective surgery using GnRH agonists/antagonists or selective progesterone receptor modulators plus concurrent iron supplementation for 3-6 months. 1, 3, 5
• Preoperative medical therapy reduces fibroid size, minimizes intraoperative blood loss, and facilitates surgical resection. 1, 2

Surgical and Interventional Management

The choice depends on three critical factors: fertility desires, symptom severity, and fibroid location (FIGO classification). 1, 3

For Women Desiring Future Fertility:

Submucosal Fibroids (FIGO Types 0-2):

• Hysteroscopic myomectomy is first-line conservative surgical therapy for pedunculated submucosal fibroids <5 cm, achieving pregnancy rates of 85% and live birth rates of 65%. 1, 2, 3
• FIGO Type 0 (pedunculated) fibroids are ideal candidates with shorter hospital stays and faster recovery. 1
• FIGO Type 2 (≥50% intramural) may require laparoscopic approach depending on size and surgeon expertise. 1

Intramural Fibroids (FIGO Types 3-4):

• Laparoscopic myomectomy is preferred for ≤3 fibroids <15 cm when fertility preservation is desired. 1, 3
• Open myomectomy via anterior uterine incision is indicated for multiple fibroids, very large uteri, or when laparoscopic approach is not feasible. 1, 3
• Do NOT remove intramural fibroids that do not distort the uterine cavity, as there is no fertility benefit and added surgical risk. 2
• Intramural fibroids with cavity distortion lower implantation rates to 6% (vs. 16% without distortion) and pregnancy rates to 16% (vs. 30% in controls). 2

Subserosal Fibroids (FIGO Types 5-7):

• Asymptomatic subserosal fibroids do not warrant intervention in women desiring pregnancy, as they do not impair fertility (pregnancy rate ~34%). 1, 2
• Surgical removal is indicated only for symptomatic bulk-related complaints. 1

Important Myomectomy Risks:

• Significant intraoperative blood loss, postoperative adhesion formation affecting future fertility, uterine perforation, and need for blood transfusion. 1, 2
• When morcellation is necessary, counsel patients about the rare risk (<1 in 1000) of occult malignancy and potential for cancer spread. 5
• Use vasopressin, bupivacaine-epinephrine, misoprostol, peri-cervical tourniquet, or gelatin-thrombin matrix to reduce blood loss. 5

Broad Ligament Fibroids:

• MRI is the preferred imaging modality to define size, location, and relationship to ureters and iliac vessels. 1
• Surgical myomectomy (laparoscopic or open) is the definitive fertility-preserving treatment, with meticulous technique to protect ureters and pelvic vasculature. 1
• Uterine artery embolization is contraindicated because broad ligament fibroids receive blood supply from ovarian or other pelvic arteries. 1

For Women NOT Desiring Future Fertility:

Definitive Surgical Treatment:

• Hysterectomy (via the least invasive approach possible) provides definitive resolution with approximately 90% patient satisfaction, eliminates all fibroid-related symptoms including coexistent adenomyosis, and removes recurrence risk. 1, 2, 3
• Hysterectomy accounts for ~75% of fibroid treatments in the United States (150,000-200,000 cases annually). 1, 2
• Reserve hysterectomy for cases where less invasive therapies cannot provide comparable symptom relief, as it carries higher complication rates, longer hospital stays, and long-term risks (cardiovascular disease, osteoporosis, dementia). 2

Uterine Artery Embolization (UAE):

• UAE is an effective uterus-preserving option for properly selected patients who have failed medical therapy and do not desire pregnancy. 1, 2, 3
• Immediate symptom control (bleeding and bulk) occurs in 73-98% of patients, with sustained relief in 72-73% at 5 years. 1, 2
• Mean fibroid volume reduction is 42-53% at 3 months post-procedure. 1, 2
• Re-intervention rates are 28% at 5 years and 35% at 10 years, higher than hysterectomy. 1, 2
• Treatment failure is 23% at 10 years in women <40 years due to collateral ovarian artery recruitment. 2
• Anterior wall fibroids respond best; cervical fibroids have high failure rates. 2
• Post-UAE amenorrhea occurs in ~20% of women >45 years vs. 2-3% in women <45 years. 2
• UAE is effective for concurrent adenomyosis, providing long-term symptomatic relief in 65-82% of cases. 2
• Major complications occur in <3% of cases; ~10% require readmission for pain. 2
• Repeat UAE effectively controls recurrent symptoms and does not preclude subsequent surgery. 2
• Counsel patients that UAE's impact on fertility is controversial and is not recommended for women desiring future pregnancy. 2, 5

MR-Guided Focused Ultrasound (MRgFUS):

• MRgFUS provides quality-of-life improvements and 5-year re-intervention rates similar to laparoscopic myomectomy, using high-intensity ultrasound for thermal ablation without incisional damage. 1, 2, 3
• Long-term durability data remain insufficient. 1, 2
• Registry data show 54 pregnancies in 51 women, with 41% live births, 28% spontaneous abortions, and 43% pregnancy-related complications. 2

Laparoscopic Uterine Artery Occlusion (LUAO):

• LUAO decreases heavy menstrual bleeding and fibroid diameter with lower postprocedural complications and rehospitalizations compared to UAE. 2

Endometrial Ablation:

• Indicated specifically for heavy menstrual bleeding refractory to medical therapy in women who have completed childbearing. 3
• Contraindicated in women desiring future fertility due to high risk of ectopic pregnancy, preterm delivery, and stillbirth. 3

Special Clinical Scenarios

Multiple Fibroids with Concurrent Adenomyosis:

• Medical management or UAE are preferred initial approaches. 3
• Hysterectomy provides definitive treatment if medical management fails, as it eliminates both conditions. 2, 3

Perimenopausal Women:

• Medical therapy can bridge patients to menopause, allowing avoidance of surgery, as fibroid symptoms typically decline postmenopausally. 2

Acute Heavy Uterine Bleeding:

• Conservative management includes high-dose estrogens, tranexamic acid 1-1.5 g IV/PO every 6-8 hours, Foley catheter tamponade, or operative hysteroscopic intervention. 2, 5
• Emergency UAE achieves immediate symptom control in 73-98% of cases when interventional radiology is available. 2
• Emergency hysterectomy is definitive treatment for life-threatening bleeding unresponsive to medical therapy in patients who have completed childbearing. 2

Pregnancy Considerations:

• Myomectomy is NOT indicated prophylactically before pregnancy unless the patient had previous pregnancy complications related to fibroids. 5
• Women with fibroids detected in pregnancy require additional maternal and fetal surveillance due to increased risks of spontaneous abortion, preterm delivery, abnormal fetal presentation, and postpartum hemorrhage. 1, 5
• Fertility is suppressed during GnRH agonist/antagonist treatment; discontinue before attempting conception. 3

Fibroid Degeneration:

• In women with acute pelvic pain and known fibroids, perform urgent imaging to exclude twisted adnexa, ruptured ectopic pregnancy, hemorrhagic ovarian cyst, ovarian malignancy, and uterine sarcoma (especially with rapid growth in postmenopausal patients). 1

Diagnostic Imaging

• Pelvic ultrasound with Doppler is first-line diagnostic imaging (90-99% sensitivity, 98% specificity). 1
• MRI provides superior delineation of fibroid location, size, number, and can differentiate fibroids from adenomyosis and endometriosis. 1
• Saline infusion sonohysterography (SIS) improves visualization between endometrial pathologies and submucosal fibroids. 1

Common Pitfalls and Caveats

• High rates of symptom recurrence occur after discontinuation of medical therapy, particularly with GnRH agonists/antagonists, requiring long-term treatment planning. 2
• Never use combined oral contraceptives in asymptomatic fibroids in women attempting conception, as they suppress fertility. 2
• Always use add-back estrogen-progestin therapy with GnRH agents >3-6 months to prevent bone density loss. 1, 2, 3
• For fibroids >10 cm, medical therapy alone is unlikely to provide sufficient volume reduction for complete symptom resolution. 1
• Less than half of patients attempting conception after myomectomy achieve pregnancy, and of these, less than half result in live births. 2